Clustered regularly interspaced short palindromic repeats (CRISPR) system provides
adaptive immunity against plasmids and phages in prokaryotes. This system inspires the …

Simple Summary In 2017, two chimeric antigen receptor-T (CAR-T) therapies were
approved by the FDA for advanced/resistant lymphoma and acute lymphoblastic leukemia …

T cells engineered to express chimeric antigen receptors (CARs) with tumor specificity have
shown remarkable success in treating patients with hematologic malignancies and …

T cells genetically engineered to express chimeric antigen receptors (CARs) have proven—
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …

Based on engineered or bacterial nucleases, the development of genome editing
technologies has opened up the possibility of directly targeting and modifying genomic …

Autologous chimeric antigen receptor (CAR) T cells have changed the therapeutic
landscape in haematological malignancies. Nevertheless, the use of allogeneic CAR T cells …

Due to their efficient recognition and lysis of malignant cells, natural killer (NK) cells are
considered as specialized immune cells that can be genetically modified to obtain capable …

Programmed cell death protein-1 (PD-1)-mediated immunosuppression has been proposed
to contribute to the limited clinical efficacy of chimeric antigen receptor T (CAR-T) cells in …

Adoptive T cell transfer (ACT) is a new area of transfusion medicine involving the infusion of
lymphocytes to mediate antitumor, antiviral, or anti-inflammatory effects. The field has rapidly …

Cell therapies present an entirely new paradigm in drug development. Within this class,
immune cell therapies are among the most advanced, having already demonstrated …